Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donor-derived activated natural killer cells
- Development stage
- Unknown
- Lead developer
- Beijing Boren Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Donor-derived activated natural killer (NK) cells are an allogeneic adoptive cell therapy developed by Beijing Boren Hospital for the treatment of hematological malignancies, specifically acute myeloid leukemia (AML). The therapy involves isolating NK cells from a healthy donor, followed by ex vivo expansion and activation using cytokines such as interleukin-2 (IL-2) or interleukin-15 (IL-15) to enhance their anti-tumor cytotoxicity. Once infused into the patient, these activated NK cells identify and eliminate leukemic blasts through the recognition of stress-induced ligands via activating receptors (e.g., NKG2D, NKp46) and the subsequent release of cytotoxic granules containing perforin and granzymes. This approach is particularly investigated as a consolidation therapy or a bridge to hematopoietic stem cell transplantation in patients with refractory or relapsed AML.
- Other names
- allogeneic activated natural killer cellsdonor-derived NK cellsactivated NK cells
02
Targets
MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on donor-derived activated natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donor-derived activated natural killer cells.